Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption

Osteoporosis International

Volumn 21, Issue 8, 2010, Pages 1437-1447

  Matsubara, M ^a   Yamachika, E ^a   Tsujigiwa, H ^a   Mizukawa, N ^a   Ueno, T ^a   Murakami, J ^a   Ishida, N ^a   Kaneda, Y ^a   Shirasu, N ^a   Takagi, S ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bone metabolism; Bone resorption; DHNA; FK506; Osteoporosis; Osteoporosis treatment

Indexed keywords

1,4 DIHYDROXY 2 NAPHTHOIC ACID; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN; NAPHTHOQUINONE; RANTES; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; COLON; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LACTOBACILLUS BIFIDUS; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROPIONIBACTERIUM FREUDENREICHII; RADIOGRAPHY;

ANIMALS; BODY WEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CELLS, CULTURED; COLON; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EATING; FEMUR; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; KIDNEY; MALE; MICE; MICE, INBRED ICR; NAPHTHOLS; OSTEOCLASTS; OSTEOPOROSIS; TACROLIMUS;

EID: 77954543572     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1075-y     Document Type: Article

References (40)

1. JA Kanis LJ Melton 3rd C Christiansen, et al. 1994 The diagnosis of osteoporosis J Bone Miner Res 9 1137 1141 10.1002/jbmr.5650090802 1:STN:280:DyaK2M%2FmslSisA%3D%3D 7976495
2. DG Roodman 1996 Advances in bone biology: the osteoclast Endocrine Rev 17 308 332 1:CAS:528:DyaK28Xltl2mtrY%3D
3. MA Rodino E Shane 1998 Osteoporosis after organ transplantation Am J Med 104 459 469 10.1016/S0002-9343(98)00081-3 1:STN:280:DyaK1c3ovFaksg%3D%3D 9626030 (Pubitemid 28274851)
4. H Kawaguchi N Manabe C Miyaura, et al. 1999 Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia J Clin Invest 104 229 237 10.1172/JCI5705 1:CAS:528:DyaK1MXkvFagsbg%3D 10430604
5. A Cohen E Shane 2003 Osteoporosis after solid organ and bone marrow transplantation Osteoporos Int 14 617 630 10.1007/s00198-003-1426-z 12908095 (Pubitemid 41490345)
6. A Monegal M Navasa N Guañabens, et al. 2001 Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics Osteoporos Int 12 484 492 10.1007/s001980170094 1:STN:280:DC%2BD3Mzpt1entQ%3D%3D 11446565 (Pubitemid 32607092)
7. S Kirino J Fukunaga S Ikegami, et al. 2004 Regulation of bone metabolism in immunosuppressant (FK506)-treated rats J Bone Miner Res 22 554 560 10.1007/s00774-004-0523-1 1:CAS:528:DC%2BD2cXosVSksr8%3D (Pubitemid 39517875)
8. J Fukunaga T Yamaai E Yamachika, et al. 2004 Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506 Bone 34 425 431 10.1016/j.bone.2003.05.003 1:CAS:528:DC%2BD2cXhvFalu7w%3D 15003790 (Pubitemid 38314907)
9. JD Pirsch J Miller MH Deierhoi, et al. 1997 A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation Tranaplantation 63 977 983 10.1097/00007890-199704150-00013 1:CAS:528:DyaK2sXjtFerurw%3D (Pubitemid 27173021)
10. K Hengming Q Huai 2003 Structures of calcineurin and its complexes with immunophilins-immunosuppressants Biochem Biophys Res Commun 311 1095 1102 10.1016/S0006-291X(03)01537-7 (Pubitemid 37393432)
11. J Liu JD Farmer WS Lane, et al. 1991 Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 807 815 10.1016/0092-8674(91)90124-H 1:CAS:528:DyaK3MXlsV2qu7w%3D 1715244
12. T Goto T Kino H Hatanaka, et al. 1991 FK506: historical perspectives Transplant Proc 23 2713 2717 1:CAS:528:DyaK38Xht1Siu78%3D 1721254
13. DA Fruman CB Klee BE Bierer, et al. 1992 Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine A Proc Natl Acad Sci USA 89 3686 3690 10.1073/pnas.89.9.3686 1:CAS:528:DyaK38Xkt1SisLo%3D 1373887
14. A Cohen P Sambrook E Shane 2004 Management of bone loss after organ transplantation J Bone Miner Res 19 1919 1932 10.1359/JBMR.040912 15537434 (Pubitemid 41103406)
15. E Shane V Addesso PB Namerow, et al. 2004 Alendronateversus calcitriol for the prevention of bone loss after cardiac transplantation N Engl J Med 350 767 776 10.1056/NEJMoa035617 1:CAS:528:DC%2BD2cXhsVems74%3D 14973216 (Pubitemid 38209646)
16. BA Crawford C Kam J Pavlovic, et al. 2006 Zoledronic acidprevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial Ann Intern Med 144 239 248 1:CAS:528:DC%2BD28Xit1Kjsrk%3D 16490909
17. F Atamaz S Hepguler M Akyildiz, et al. 2006 Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation Osteoporos Int 17 942 949 10.1007/s00198-006-0082-5 1:CAS:528:DC%2BD28XkvVCnurg%3D 16550299 (Pubitemid 43781510)
18. RNJ de Nijs JWG Jacobs A Algra, et al. 2004 Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies Osteoporosis Int 15 589 602 10.1007/s00198-004-1614-5
19. M Fukunaga K Kushida H Kishimoto, et al. 2002 A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial Osteoporos Int 13 971 979 10.1007/s001980200135 1:CAS:528:DC%2BD38XptFGitrY%3D 12459940 (Pubitemid 36050275)
20. JR Green Y Seltenmeyer KA Jaeggi, et al. 1997 Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models Pharmacol Toxicol. 80 225 230 10.1111/j.1600-0773.1997.tb01964.x 1:CAS:528:DyaK2sXjtlSnt7g%3D 9181601
21. JT Chang L Green J Beitz 2003 Renal failure with the use of zoledronic acid N Engl J Med 349 1676 1679 10.1056/NEJM200310233491721 1:CAS:528: DC%2BD3sXosFakurw%3D 14573746 (Pubitemid 37288581)
22. B Mehrotra S Ruggiero 2006 Bisphosphonate complications including osteonecrosis of the jaw Hematology 2006 356 360 10.1182/asheducation-2006.1.356
23. N Yarom R Yahalom Y Shoshani, et al. 2007 Osteonecrosis of the jaw induced by orally administered bisphospnates: incidence, clinical features, predisposing factors and treatment outcome Osteoporos Int 18 1363 1370 10.1007/s00198-007-0384-2 1:CAS:528:DC%2BD2sXhtVagurrI 17598065 (Pubitemid 47389465)
24. J Bagan J Blade JM Cozar, et al. 2007 Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates Med Oral Patol Oral Cir Bucal 12 336 340
25. CE Dempfle M Borggrefe 2005 Vermeidung von Notfallsituationen bei gerinnungshemmender Therapie mit Vitamin-K-Antagonisten Der Internist 46 1006 1013 10.1007/s00108-005-1479-5 1:STN:280:DC%2BD2MvmsVyhsw%3D%3D 16082525 (Pubitemid 41260029)
26. Y Okada Y Tsuzuki J Miyazaki S Miura, et al. 2006 Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing Gut 55 5 681 688 10.1136/gut.2005.070490 1:CAS:528: DC%2BD28Xksl2hurs%3D 16299037
27. T Kaneko H Mori M Iwata, et al. 1993 Growth stimulator for bifidobacteria produced by Propionibacterium freudenreichii and several intestinal bacteria J Dairy Sci 77 393 404 10.3168/jds.S0022-0302(94)76965-4
28. T Kaneko 1999 A novel bifidogenic growth stimulator produced by Propionibacterium freudenreichii Bioscience Microflora 18 2 73 80 1:CAS:528:DC%2BD3cXivVCjtA%3D%3D
29. A Suzuki K Mitsuyama H Koga, et al. 2006 Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study Nutrion 22 1 76 81 10.1016/j.nut.2005.04.013 1:CAS:528:DC%2BD28XhtFWiurc%3D
30. A Nanbara R Nukada S Nagai 1983 Inhibition by acetic and propionic acids of the growth of Propionibacterium shermanii J Ferment Technol 61 551 556
31. K Iwasa K Hojo N Yoda, et al. 2002 Isolation and identification of a new bifidogenic growth stimulator produced by Propionibacterium freudenreichii ET-3 Biosci Biotechnol Biochem 66 3 679 681 10.1271/bbb.66.679
32. J Iwamoto T Takeda Y Sato, et al. 2007 Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats Exp Anim 56 2 103 110 10.1538/expanim.56.103 1:CAS:528:DC%2BD2sXmt1aiu7c%3D 17460355 (Pubitemid 46711794)
33. Y Kinoshita M Taguchi A Takeshita, et al. 2005 1,25-Dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis J Clin Endocrinol Metab 90 12 6727 6731 10.1210/jc.2005-1380 1:CAS:528:DC%2BD2MXhtlaltLvF 16159932 (Pubitemid 41759340)
34. A Gal-Moscovici SM Sprague EV Lerma 2007 Treatment of renal osteodystrophy Clin Rev Bone Mineral Metab 5 27 38 10.1007/BF02736669 1:CAS:528:DC%2BD2sXhtlaqu7bF (Pubitemid 350239179)
35. R Mrvos M Hodgman EP Krenzelok 1997 Tacrolimus (FK506) overdose: a report of five cases J Toxicol Clin Toxicol 35 4 395 399 10.3109/15563659709043372 1:STN:280:DyaK2szkvVSgsQ%3D%3D 9204100
36. E Jimi I Nakamura LT Duong, et al. 1999 Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells Exp Cell Res 247 84 93 10.1006/excr.1998.4320 1:CAS:528:DyaK1MXht12ku7w%3D 10047450 (Pubitemid 29393964)
37. T Akatsu N Takahashi N Udagawa, et al. 1991 Role of prostaglandins in interleukin-1 bone resorption in mice vitro J Bone Miner Res 6 183 190 10.1002/jbmr.5650060212 1:CAS:528:DyaK3MXltlelu7Y%3D 2028836
38. K Kobayashi N Takahashi E Jimi, et al. 2000 Tumor necrosis factor stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction J Exp Med 191 2 275 286 10.1084/jem.191.2.275 1:CAS:528:DC%2BD3cXntFenug%3D%3D 10637272 (Pubitemid 30060917)
39. Y Azuma K Kaji R Katogi, et al. 2000 Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts J Biol Chem 275 7 4858 4864 10.1074/jbc.275.7.4858 1:CAS:528:DC%2BD3cXhsVyms74%3D 10671521 (Pubitemid 30108878)
40. CM Gordon E Binello MS LeBoff, et al. 2006 Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokinesand bone density in cystic fibrosis Osteoporos Int 17 783 790 10.1007/s00198-005-0058-x 1:CAS:528:DC%2BD28XjsVertrY%3D 16541207